Answers are grounded in this paper and cite their sources.
Objective: Carboplatin, a platinum-based chemotherapeutic agent, often causes dose‑limiting nephrotoxicity. Thymol, a natural monoterpene phenol, has antioxidant and anti‑inflammatory properties. This study aimed to determine whether thymol protects against carboplatin‑induced kidney injury in male rats. Methods: Fifty adult male albino rats were randomly divided into five groups (n=10 each): control (distilled water), olive oil (vehicle), thymol alone (40 mg/kg/day orally), carboplatin alone (50 mg/kg single intraperitoneal), and carboplatin plus thymol (same doses, thymol started 24 hours after carboplatin). After three months, serum renal function markers, oxidative stress indices (malondialdehyde [MDA], 8‑hydroxy‑2′‑deoxyguanosine [8‑OHdG]), circulating Nrf2, antioxidant enzymes (superoxide dismutase [SOD], catalase [CAT], glutathione peroxidase [GPx], reduced glutathione [GSH]), pro‑inflammatory cytokines (NF‑κB p65, TNF‑α, IL‑6, IL‑1β), and renal histopathology were assessed. Data were analysed by one‑way ANOVA with Tukey’s post hoc test (p<0.05). Results: Carboplatin significantly increased serum creatinine, urea, and uric acid; elevated MDA, 8‑OHdG, and circulating Nrf2; depleted SOD, CAT, GSH, and GPx; and raised NF‑κB, TNF‑α, IL‑6, and IL‑1β (p<0.05). Renal histology showed tubular degeneration, vascular congestion, and inflammatory infiltration. Co‑administration of thymol reversed most of these changes towards control values and markedly improved histological architecture. Conclusion: Thymol attenuates carboplatin‑induced nephrotoxicity in male rats, likely by reducing oxidative damage and suppressing inflammatory signalling. These findings support further investigation of thymol as a potential adjunct to platinum‑based chemotherapy.
No takes yet. Share an insight, caveat, or question.
Hameed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: